Sanofi announced 2025 first-half revenue of EUR 19.9 billion (USD 22.8 billion), up 9.9% year-on-year, driven by strong performance in immunology and vaccines. Dupixent (dupilumab) remained the growth engine with sales of EUR 7.3 billion (USD 8.4 billion, +20.7%), supported by new approvals for chronic spontaneous urticaria and bullous pemphigoid in the US. The respiratory syncytial virus (RSV) antibody Beyfortus (nirsevimab) surged 79% to EUR 356 million (USD 407 million), though it faces competition from MSD's newly approved Enflonsia (clesrovimab).

Rare disease therapies contributed EUR 3.1 billion (+34%), led by haemophilia drug Altuviiio (efanesoctocog alfa) at EUR 542 million (+95.4%). Sanofi completed nine business development deals in seven months, including the USD 9.5 billion acquisition of Blueprint Medicines. The company maintains full-year guidance of high single-digit revenue growth, with tolebrutinib potentially becoming the first BTK inhibitor for multiple sclerosis upon anticipated September approval.

According to PharmCube's NextBiopharm® database, Dupixent sales have consistently expanded each year despite continuous slow-down. Click here to request a free trial for NextBiopharm®.